ILLUMINA INC (ILMN)
US4523271090 - Common Stock
Overall ILMN gets a fundamental rating of 4 out of 10. We evaluated ILMN against 58 industry peers in the Life Sciences Tools & Services industry. The financial health of ILMN is average, but there are quite some concerns on its profitability. ILMN has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
ILMN had positive earnings in the past year.
In the past year ILMN had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: ILMN reported negative net income in multiple years.
In the past 5 years ILMN always reported a positive cash flow from operatings.
1.2 Ratios
The Return On Assets of ILMN (-12.84%) is comparable to the rest of the industry.
ILMN has a Return On Equity (-22.48%) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -12.84% | ||
| ROE | -22.48% | ||
| ROIC | N/A |
ROA(3y)-14.14%
ROA(5y)-4.02%
ROE(3y)-26.62%
ROE(5y)-8.83%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ILMN's Gross Margin of 61.36% is amongst the best of the industry. ILMN outperforms 89.47% of its industry peers.
In the last couple of years the Gross Margin of ILMN has declined.
The Profit Margin and Operating Margin are not available for ILMN so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 61.36% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.6%
GM growth 5Y-2.46%
2. Health
2.1 Basic Checks
ILMN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ILMN has more shares outstanding
The number of shares outstanding for ILMN has been increased compared to 5 years ago.
ILMN has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 3.14 indicates that ILMN is not in any danger for bankruptcy at the moment.
ILMN's Altman-Z score of 3.14 is fine compared to the rest of the industry. ILMN outperforms 66.67% of its industry peers.
The Debt to FCF ratio of ILMN is 4.07, which is a neutral value as it means it would take ILMN, 4.07 years of fcf income to pay off all of its debts.
ILMN has a better Debt to FCF ratio (4.07) than 78.95% of its industry peers.
ILMN has a Debt/Equity ratio of 0.26. This is a healthy value indicating a solid balance between debt and equity.
ILMN has a Debt to Equity ratio of 0.26. This is comparable to the rest of the industry: ILMN outperforms 50.88% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | 4.07 | ||
| Altman-Z | 3.14 |
ROIC/WACCN/A
WACC11.99%
2.3 Liquidity
A Current Ratio of 1.75 indicates that ILMN should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.75, ILMN is doing worse than 68.42% of the companies in the same industry.
ILMN has a Quick Ratio of 1.36. This is a normal value and indicates that ILMN is financially healthy and should not expect problems in meeting its short term obligations.
ILMN has a Quick ratio of 1.36. This is in the lower half of the industry: ILMN underperforms 73.68% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.75 | ||
| Quick Ratio | 1.36 |
3. Growth
3.1 Past
The earnings per share for ILMN have decreased strongly by -22.12% in the last year.
ILMN shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -31.38% yearly.
ILMN shows a small growth in Revenue. In the last year, the Revenue has grown by 1.03%.
ILMN shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 6.21% yearly.
EPS 1Y (TTM)-22.12%
EPS 3Y-42.18%
EPS 5Y-31.38%
EPS Q2Q%12.5%
Revenue 1Y (TTM)1.03%
Revenue growth 3Y11.62%
Revenue growth 5Y6.21%
Sales Q2Q%-1.01%
3.2 Future
The Earnings Per Share is expected to grow by 59.70% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 8.50% on average over the next years. This is quite good.
EPS Next Y-15.08%
EPS Next 2Y71.72%
EPS Next 3Y53.38%
EPS Next 5Y59.7%
Revenue Next Year0.79%
Revenue Next 2Y3.89%
Revenue Next 3Y5.33%
Revenue Next 5Y8.5%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 136.85, the valuation of ILMN can be described as expensive.
ILMN's Price/Earnings ratio is a bit cheaper when compared to the industry. ILMN is cheaper than 61.40% of the companies in the same industry.
ILMN's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 24.41.
With a Price/Forward Earnings ratio of 46.95, ILMN can be considered very expensive at the moment.
63.16% of the companies in the same industry are more expensive than ILMN, based on the Price/Forward Earnings ratio.
ILMN's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 20.59.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 136.85 | ||
| Fwd PE | 46.95 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ILMN indicates a somewhat cheap valuation: ILMN is cheaper than 63.16% of the companies listed in the same industry.
ILMN's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. ILMN is cheaper than 68.42% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 52.42 | ||
| EV/EBITDA | 50.85 |
4.3 Compensation for Growth
ILMN's earnings are expected to grow with 53.38% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y71.72%
EPS Next 3Y53.38%
5. Dividend
5.1 Amount
ILMN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ILLUMINA INC
NASDAQ:ILMN (7/26/2024, 7:00:02 PM)
After market: 120.43 0 (0%)120.43
+3.13 (+2.67%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap19.18B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 136.85 | ||
| Fwd PE | 46.95 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -12.84% | ||
| ROE | -22.48% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 61.36% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.45
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.75 | ||
| Quick Ratio | 1.36 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-22.12%
EPS 3Y-42.18%
EPS 5Y
EPS Q2Q%
EPS Next Y-15.08%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)1.03%
Revenue growth 3Y11.62%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y